Clinica BavieraXMAD:CBAV +0.71%100 Net Margin % is 16.90% as of Mar. 2026, which is 33% above its 10-year median of 12.66. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €41.30 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 85.78% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Clinica Baviera's Net Income for the
three
months ended in Mar. 2026 was €14.7 Mil. Clinica Baviera's Revenue for the
three
months ended in Mar. 2026 was €87.0 Mil. Therefore, Clinica Baviera's net margin for the quarter that ended in Mar. 2026 was 16.90%.
The historical rank and industry rank for Clinica Baviera's Net Margin % or its related term are showing as below:
XMAD:CBAV'
s Net Margin % Range Over the Past 10 Years
Min: 8.64 Med: 12.66 Max: 15.99
Current: 14.23
XMAD:CBAV's Net Margin % is ranked better than 85.78% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs XMAD:CBAV: 14.23
Clinica Baviera (XMAD:CBAV) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Clinica Baviera Net Margin % Related Terms
Clinica Baviera Net Margin % Historical Data
* Premium members only.
The historical data trend for Clinica Baviera's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:CBAV vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Clinica Baviera's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's Net Margin % distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinica Baviera (XMAD:CBAV) has a Net Margin % of 16.90% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Clinica Baviera and its competitors. This is 33% above median its historical median of 12.66. Over the past decade, Clinica Baviera's Net Margin % has ranged from 8.64 to 15.99. According to the industry distribution chart, Clinica Baviera ranks #29 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 14.2%.
Is Clinica Baviera's Net Margin % too high?
Clinica Baviera's current Net Margin % of 16.90% is 33% above median its 10-year median of 12.66. Over the past 10 years, this metric has ranged from a low of 8.64 to a high of 15.99. Based on the distribution chart, Clinica Baviera ranks #29 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #29 out of 204 companies for Net Margin %. This places Clinica Baviera in the top 14% of its industry — outperforming the majority of peers. Historically, Clinica Baviera's own Net Margin % has ranged from 8.64 to 15.99 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Clinica Baviera and its competitors. Clinica Baviera's current Net Margin % is 16.90%, which is 33% above median its own 10-year median of 12.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.30, compared to a current price of €56.60 — trading 37% above its estimated fair value. The current Net Margin % is 16.90%, which is 33% above median its 10-year median of 12.66. Clinica Baviera's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current Net Margin % is 16.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €56.60 is trading 37% above its estimated GF Value™ of €41.30.
GuruFocus considers Clinica Baviera to be Significantly Overvalued.
Key valuation signals for XMAD:CBAV:
Net Margin %: 16.90% (33% above median its 10-year median of 12.66)
GF Value™: €41.30 vs. price of €56.60 (37% above fair value)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for XMAD:CBAV
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 
